Business and Organization (Details) $ / shares in Units, $ in Thousands			3 Months Ended	9 Months Ended
	May 09, 2022 USD ($) $ / shares shares	Apr. 29, 2022 USD ($) $ / shares shares	Jun. 30, 2022 USD ($)	Sep. 30, 2022 USD ($) employee $ / shares	Sep. 30, 2021 USD ($)	Dec. 31, 2021 $ / shares
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of sales employees | employee				180
Common stock, par value (in dollars per share) | $ / shares				$ 0.01		$ 0.01
Value of consideration shares				$ 172,000	$ 0
Gain on sale of GeneDx				$ 15,365	$ 0
Common Stock
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Stock price (in dollars per share) | $ / shares	$ 2.44
ModeX Therapeutics Inc
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total aggregate consideration	$ 300,000
Common stock, par value (in dollars per share) | $ / shares	$ 0.01
Shares deposited in escrow (as a percent)	10.00%
Escrow deposit, term	12 months
Business acquisition, equity awards issued	$ 12,400
Equity interest issued or issuable, period following closing date	4 years
Escrow Period	4 years
Lockup and voting agreement, period following closing date	4 years
Consideration shares (as a percent)	88.00%
ModeX Therapeutics Inc | Former Stockholder
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Business acquisition, equity awards issued	$ 2,600
ModeX Therapeutics Inc | Common Stock
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of shares issued in business combination (in shares) | shares	89,907,310
Value of consideration shares	$ 221,700
Stock price (in dollars per share) | $ / shares	$ 2.44
Detect Genomix | Milestone Consideration, Tranche One
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Shareholder agreement, extension period		1 year
Detect Genomix | Milestone Consideration, Tranche Two
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Shareholder agreement, extension period		6 months
Detect Genomix | Sema4
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Total aggregate consideration		$ 447,000
Number of shares issued in business combination (in shares) | shares		80,000,000
Payments to acquire business		$ 150,000
Additional revenue-based milestones		150,000
Total upfront consideration transferred		$ 322,000
Gain on sale of GeneDx			$ 15,400
Outstanding shares held (as a percent)		5.00%
Detect Genomix | Sema4 | Common Class A
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Common stock, par value (in dollars per share) | $ / shares		$ 0.0001